Lunsumio is a cancer medicine used to treat adults with follicular lymphoma that does not respond to (refractory) or has come back (relapsed) after at least two previous treatments. Follicular lymphoma is rare, and Lunsumio was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 16 November 2021. Further information on the orphan designation can be found here: [ema.europa.eu/medicines/human/orphan-designations/EU3212517](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2517) Lunsumio contains the active substance mosunetuzumab.
Therapeutic Indication
### Therapeutic indication Lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.
Therapeutic Area (MeSH)
N/AATC Code
L01FX25
ATC Item
mosunetuzumab
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| mosunetuzumab | N/A | 莫妥珠单抗 |
EMA Name
Lunsumio
Medicine Name
Lunsumio
Aliases
N/ANo risk management plan link.
